Trials / Unknown
UnknownNCT03182634
The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) Trial
A Multiple Parallel Cohort, Multi-centre Phase IIa Trial Aiming to Provide Proof of Principle Efficacy for Designated Targeted Therapies in Patients With Advanced Breast Cancer Where the Targetable Mutation is Identified Through ctDNA
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 1,150 (estimated)
- Sponsor
- Institute of Cancer Research, United Kingdom · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
plasmaMATCH is a multi-centre phase IIa umbrella trial platform consisting of a ctDNA screening component and a therapeutic component. plasmaMATCH aims to assess whether ctDNA screening can be used to detect patient subgroups who will be sensitive to targeted therapies, and will also assess the safety and activity of the targeted treatments.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fulvestrant | |
| DRUG | Neratinib | |
| DRUG | AZD5363 | |
| DRUG | Olaparib | |
| DRUG | AZD6738 |
Timeline
- Start date
- 2016-12-15
- Primary completion
- 2022-11-01
- Completion
- 2023-11-01
- First posted
- 2017-06-09
- Last updated
- 2019-01-22
Locations
19 sites across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT03182634. Inclusion in this directory is not an endorsement.